Nasdaq · Healthcare
Immunocore Holdings plc (IMCR)
As-reported financials and recent SEC filings for Immunocore Holdings plc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$400.0M
Net income
$-35.5M
Net margin
-8.9%
Diluted EPS
$-0.71
ROE
-9.3%
P/E (TTM)
—
Market cap
$1.57B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $400.0M | $310.2M | $249.4M | $174.4M | $36.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $-45.4M | $-70.5M | $-59.6M | $-51.7M | $-174.6M |
| Net income | $-35.5M | $-51.1M | $-55.3M | $-52.5M | $-180.0M |
| Diluted EPS | $-0.71 | $-1.02 | $-1.13 | $-1.15 | $-4.24 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →42026-05-28
View on EDGAR →8-K2026-05-27
View on EDGAR →1442026-05-22
View on EDGAR →Go deeper on IMCR
Search Immunocore Holdings plc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.